Table 4.
3-, 5-and 10-year prevalence estimates (95% confidence intervals) per 100,000 of myeloid malignancies: Haematological Malignancy Research Network diagnoses Sept 2004 to Aug 2013, followed through to Feb 2015.
| Total |
Males |
Females |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| 3 Year | 5 Year | 10 Year | 3 Year | 5 Year | 10 Year | 3 Year | 5 Year | 10 Year | |
| All myeloid malignancies | 34.3(32.4–36.3) | 50.0(47.7–52.4) | 79.2(86.2–82.2) | 37.7(34.8–40.6) | 55.4(51.9–58.9) | 82.6(78.3–87.0) | 31.2(28.6–33.7) | 45.0(42.0–8.1) | 76.0(72.0–80.0) |
| Acute myeloid leukaemia | 4.4(3.7–5.1) | 6.0(5.2–6.8) | 9.0(8.0–10.0) | 5.1(4.1–6.2) | 7.1(5.9–8.4) | 10.4(8.9–11.9) | 3.7(2.8–4.6) | 4.9(3.9–5.9) | 7.6(6.4–8.9) |
| AML-not otherwise specified | 2.1(1.6–2.6) | 2.7(2.1–3.2) | 3.8(3.1–4.4) | 2.7(1.9–3.5) | 3.6(2.7–4.5) | 4.9(3.8–5.9) | 1.5(1.0–2.1) | 1.8(1.2–2.4) | 2.8(2.0–3.6) |
| AML with myelodysplasia related changes | 0.5(0.1–0.8) | 0.6(0.3–1.0) | 0.6(0.3–1.0) | 0.4(0.1–0.7) | 0.5(0.2–0.8) | 0.5(0.2–0.8) | 0.4(0.2–0.6) | 0.6(0.3-–0.8) | 0.6(0.3–0.8) |
| AML with NPM mutation | 0.6(0.4–0.9) | 1.0(0.6–1.3) | 1.2(0.8–1.6) | 0.8(0.3–1.2) | 0.9(0.4–1.3) | 1.1(0.6–1.6) | 0.5(0.2–0.8) | 1.0(0.6–1.5) | 1.3(0.7–1.8) |
| Acute promyelocytic leukaemia | 0.6(0.4–0.9) | 0.9(0.6–1.2) | 1.8(1.4–2.3) | 0.6(0.2–0.9) | 0.9(0.5–1.4) | 2.0(1.3–2.6) | 0.7(0.3–1.1) | 0.9(0.4–1.3) | 1.7(1.1–2.3) |
| AML, probable therapy related | 0.1(0.0–0.3) | 0.2(0.0–0.3) | 0.2(0.0–0.3) | 0.1(0.0–0.3) | 0.2(0.0–0.4) | 0.2(0.0–0.4) | 0.2(0.0–0.3) | 0.2(0.0–0.3) | 0.2(0.0–0.4) |
| AML with core binding factors | 0.4(0.2–0.6) | 0.6(0.3–0.8) | 1.3(0.8–1.6) | 0.4(0.1–0.7) | 0.8(0.3–1.2) | 1.4(0.8–1.9) | 0.3(0.1–0.6) | 0.4(0.1–0.7) | 1.1(0.6–1.5) |
| AML with MLL(11q23) | 0.1(0.0–0.2) | 0.1(0.0–0.2) | 0.(0.1–0.5) | 0.1(0.0–0.3) | 0.1(0.0–0.3) | 0.4(0.1–0.6) | 0.1(0.0–0.3) | 0.1(0.0–0.3) | 0.3(0.0–0.5) |
| Myelodysplastic syndromes (MDS) | 6.3(5.5–7.1) | 8.7(7.7–9.6) | 10.9(9.8–12.0) | 8.7(7.3–10.1) | 11.7(10.1–13.3) | 14.4(12.6–16.2) | 4.0(3.1–4.9) | 5.8(4.7–6.9) | 7.5(6.3–8.8) |
| Refractory cytopenia with multilineage dysplasia | 3.1(2.5–3.6) | 4.2(3.5–4.8) | 5.1(4.3–5.9) | 4.7(3.7–5.7) | 6.4(5.2–7.6) | 7.7(6.4–9.0) | 1.5(1.0–2.1) | 2.1(1.4–2.7) | 2.7(1.9–3.4) |
| Refractory anaemia with excess blasts | 1.7(1.2–2.1) | 2.0(1.5–2.4) | 2.3(1.8–2.8) | 2.3(1.6–3.0) | 2.7(1.9–3.4) | 3.0(2.1–3.8) | 1.0(0.6–1.5) | 1.3(0.8–1.8) | 1.7(1.1–2.3) |
| Refractory anaemia with ring sideroblasts | 1.3(0.9–1.7) | 2.1(1.6–2.6) | 3.0(2.4–3.5) | 1.6(1.0–2.1) | 2.5(1.8–3.3) | 3.6(2.7–4.5) | 1.0(0.6–1.5) | 1.7(1.1–2.3) | 2.3(1.6–3.0) |
| Myeloproliferative neoplasms (MPN) | 21.7(20.2–23.3) | 33.2(31.3–35.0) | 56.8(54.2–59.3) | 21.6(19.4–23.8) | 33.9(31.2–36.7) | 54.1(51.3–58.3) | 21.8(19.7–24.0) | 32.4(29.8–35.0) | 58.6(55.1–62.1) |
| Chronic MPNsa | 16.8(15.4–18.1) | 25.7(24.0–27.3) | 44.4(42.2–46.6) | 16.4(14.5–18.3) | 25.6(23.2–27.9) | 41.1(38.0–44.1) | 17.1(15.2–19.0) | 25.8(23.5–28.1) | 47.6(44.4–50.7) |
| Chronic myeloid leukaemia | 3.2(2.6–3.7) | 4.7(4.0–5.4) | 8.5(7.5–9.5) | 3.6(2.7–4.5) | 5.6(4.5–6.7) | 10.1(8.6–11.7) | 2.8(2.0–3.5) | 3.8(2.9–4.7) | 6.9(5.7–8.1) |
| Myelofibrosis | 1.5(1.1–1.9) | 2.0(1.5–2.5) | 2.5(1.9–3.0) | 1.5(0.9–2.1) | 2.1(1.4–2.8) | 2.5(1.8–3.3) | 1.4(0.9–2.0) | 1.8(1.2–2.5) | 2.4(1.7–3.1) |
| MDS/MPN | 1.9(1.5–2.4) | 2.3(1.8–2.8) | 2.6(2.0–3.1) | 2.3(1.5–3.0) | 2.6(1.8–3.4) | 2.9(2.1–3.7) | 1.6(1.0–2.2) | 2.0(1.3–2.6) | 2.3(1.6–3.0) |
| Chronic myelomonocytic leukaemia | 1.2(0.8–1.6) | 1.5(1.1–1.9) | 1.7(1.3–2.2) | 1.4(0.9–2.0) | 1.8(1.2–2.4) | 2.0(1.3–2.6) | 1.0(0.5–1.4) | 1.2(0.7–1.8) | 1.5(0.9–2.1) |
a
Polycythaemia vera, essential thrombocythaemia, MPNs unclassified.